AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03504566
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telmisartan
Trial: NCT03504566
Drug: Sulodexide
RxNorm normalized name: sulodexide
DrugBank: Sulodexide (DB06271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulodexide
Trial: NCT00003681
Drug: amifostine trihydrate
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02262481
Drug: dydrogesterone
RxNorm normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00218374
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin initiated up to a daily dose of 2400mg PO x 5 weeks
Trial: NCT01321788
Drug: TINZAPARIN
RxNorm normalized name: Tinzaparin
DrugBank: Tinzaparin (DB06822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible women following cesarean section will randomly receive once-daily injections of study drug (4,500 IU tinzaparin sodium within 12 to 24 hours postpartum and continued for two (2) weeks postpartum.
Trial: NCT02200848
Drug: Lenalidomide, Ibrutinib, Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose level -2 Ibrutinib 280 mg; Lenalidomide 2.5 mg; Rituximab 375 mg/m2 Level -1 Ibrutinib 420 mg; Lenalidomide 2.5 mg; Rituximab 375 mg/m2 Level 1 Ibrutinib 420 mg; Lenalidomide 5 mg; Rituximab 375 mg/m2 Level 2 Ibrutinib 420 mg; Lenalidomide 10 mg; Rituximab 375 mg/m2 Level 3 Ibrutinib 420 mg; Lenalidomide 15 mg; Rituximab 375 mg/m2
Trial: NCT02606552
Drug: Dabigatrain plus aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran (Pradaxa®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with atrial fibrillation. Aspirin is indicated for the prevention of stent thrombosis and myocardial infarction in patients treated with drug-eluting stents. Patients will be randomized to stop clopidogrel (maintain dabigatran + aspirin) at 3 months after PCI.
Trial: NCT05847413
Drug: Verapamil
RxNorm normalized name: Verapamil
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive oral verapamil for 12 weeks
Trial: NCT02170766
Drug: BIBR 1048 low1
RxNorm normalized name: bibrocathol
DrugBank: Bibrocathol (DB13818)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02170766
Drug: BIBR 1048 low2
RxNorm normalized name: bibrocathol
DrugBank: Bibrocathol (DB13818)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02280174
Drug: linagliptin
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: linagliptin 5 mg/d for12 weeks
Trial: NCT00666757
Drug: duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30-120 milligrams (mgs) orally daily for 12 weeks
Trial: NCT00666757
Drug: citalopram
RxNorm normalized name: Citalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20-40 mgs orally daily for 12 weeks
Trial: NCT00666757
Drug: paroxetine
RxNorm normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20-50 mgs orally daily for 12 weeks
Trial: NCT00666757
Drug: sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50-200 mgs orally daily for 12 weeks
Trial: NCT02597556
Drug: Albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single 400mg dose of Albendazole administered at 0, 3, 6, 9, and 12 months.
Trial: NCT02170766
Drug: BIBR 1048 high
RxNorm normalized name: HIGH DENSITY POLYETHYLENE
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02170766
Drug: Pantoprazole
RxNorm normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00053547
Drug: paricalcitol injection
RxNorm normalized name: paricalcitol Injection
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01982253
Drug: Fasiglifam
RxNorm normalized name: Fasiglifam
DrugBank: Fasiglifam (DB12491)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasiglifam tablets
Trial: NCT01982253
Drug: Placebo to fasiglifam
DrugBank: Fasiglifam (DB12491)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasiglifam placebo-matching tablets
Trial: NCT03508856
Drug: Ingenol Mebutate (Picato®) 0.015% gel
DrugBank: Ingenol mebutate (DB05013)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01231581
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous gemcitabine infused over 30 minutes weekly for 7 weeks followed by one week of rest from treatment. Subsequent cycles will consist of 1000 mg/m2 intravenous infusion over 30 minutes on days 1, 8, and 15 followed by 1 week of rest from treatment for each 28-day treatment period.
Trial: NCT01879228
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The GPA test as described in the primary outcome section will be performed at baseline and after 6 months of therapy in the Sitagliptin and placebo arms. Furthermore, evaluation of endogenous GLP-1 levels will be assessed by a mixed meal tolerance test compared at baseline and 6 months.
Trial: NCT00094406
Drug: Carbon Monoxide
RxNorm normalized name: carbon monoxide
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01609920
Drug: Gadofosveset enhanced MRL of axillary lymph nodes
RxNorm normalized name: gadofosveset
DrugBank: Gadofosveset trisodium (DB06705)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A MRL of the axilla will be performed before and after administration of a single IV bolus injection of gadofosveset of an equivalent of 0.03 mmol Gd/kg body weight at an injection speed of 1.5 mL/sec., followed by a saline flush of 25 mL at an injection speed of 1.5 mL/sec.
Trial: NCT00139256
Drug: Betamethasone
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone injection
Trial: NCT00473525
Drug: PF-00734200 20 mg QD
RxNorm normalized name: cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg QD
Trial: NCT00473525
Drug: PF-00734200 5 mg QD
RxNorm normalized name: haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg QD
Trial: NCT00473525
Drug: PF-00734200 2 mg QD
RxNorm normalized name: droperidol
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 mg QD
Trial: NCT00801047
Drug: Bupivacaine epidural
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.1%, fentanyl 1 mic/kg
Trial: NCT01264770
Drug: Fostamatinib and placebo injections
RxNorm normalized name: fostamatinib
DrugBank: Tamatinib (DB07159)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fostamatinib 100mg twice daily and placebo injection once every two weeks
Trial: NCT01264770
Drug: Fostamatinib and placebo injections
RxNorm normalized name: fostamatinib
DrugBank: Tamatinib (DB07159)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fostamatinib 100mg twice daily / fostamatinib 150mg once daily and placebo injection once every two weeks
Trial: NCT01264770
Drug: Fostamatinib and placebo injections
RxNorm normalized name: fostamatinib
DrugBank: Tamatinib (DB07159)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fostamatinib 100mg twice daily / fostamatinib 100mg once daily and placebo injection once every two weeks.
Trial: NCT01264770
Drug: Adalimumab and placebo of fostamatinib
RxNorm normalized name: fostamatinib
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab 40mg injection once every two weeks and placebo to fostamatinib twice daily.
Trial: NCT01264770
Drug: Placebo of fostamatinib, fostamatinib, and placebo injections
DrugBank: Tamatinib (DB07159)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection once every two weeks. Placebo to fostamatinib for six weeks, followed by fostamatinib 100mg twice daily (Group F) / fostamatinib 100mg twice daily then 150mg once daily (Group G).
Trial: NCT00963573
Drug: Loratadine
RxNorm normalized name: Loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
Trial: NCT00963573
Drug: Betamethasone
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
Trial: NCT02332954
Drug: vortioxetine
RxNorm normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The starting and recommended dose of vortioxetine is 10 mg once daily; film-coated 10 mg tablets for oral use once daily for 52 weeks.Depending on individual patient response, the dose may be increased to a maximum of 20 mg daily.
Trial: NCT01447160
Drug: Cortisone
RxNorm normalized name: Cortisone
DrugBank: Cortisone acetate (DB01380)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intraarticular infiltration with 1ml of triamcinolone hexacetonide versus intramuscular injection with 1 ml of triamcinolone acetonide
Trial: NCT00196768
Drug: Arsenic trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00196768
Drug: Trisenox
RxNorm normalized name: Trisenox
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04363450
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine loading 400mg (2 capsules) twice 12 hours apart followed by 200mg (1 capsule) twice weekly
Trial: NCT02274259
Drug: Aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aflibercept injection is given at every visit. Time to next treatment according to presence of macular edema
Trial: NCT02274259
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab injection is given at every visit. Time to next treatment according to presence of macular edema
Trial: NCT02505568
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive infliximab 5 milligram per kilogram (mg/kg) infusion at Week 0, Week 2, and Week 6 for the induction phase. Participants who complete the induction phase will continuously receive 5 mg/kg infliximab infusion every 8 weeks up to week 32 in the maintenance phase.
Trial: NCT03095066
Drug: AVP-786-28
RxNorm normalized name: AVP 21D9
DrugBank: AVP-21D9 (DB17798)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28 mg of d6-DM and 4.9 mg of Q
Trial: NCT02975921
Drug: Povidone-Iodine
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrapleural administration of Povidone-Iodine
Trial: NCT03549702
Drug: Povidone iodine 1% solution
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: irrigation of subcutaneous tissue with Povidone-Iodine prior to skin closure
Trial: NCT01649375
Drug: Secukinumab (75 mg)
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Secukinumab 75 mg s.c.
Trial: NCT03086382
Drug: Lacosamide (LCM) tablet
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment A: Single dose of Lacosamide (LCM) 200 mg given as 2 tablets of LCM 100 mg
Trial: NCT03086382
Drug: Lacosamide (LCM) syrup
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment B: Single dose of Lacosamide (LCM) 200 mg given as syrup
Trial: NCT01649375
Drug: Secukinumab (150 mg)
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Secukinumab 150 mg s.c.
Trial: NCT00382811
Drug: phenoxodiol
RxNorm normalized name: Phenoxodiol
DrugBank: Idronoxil (DB04915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg phenoxodiol three times daily in 28 day cycles.
Trial: NCT00382811
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC=2 weekly in 28 day cycles
Trial: NCT01124604
Drug: Tapentadol Hydrochloride
RxNorm normalized name: Tapentadol Hydrochloride
DrugBank: Tapentadol (DB06204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapentadol hydrochloride extended release (ER) tablets 25 to 250 milligram (mg) will be administered orally twice daily for 12 weeks. Dose will be adjusted as per Investigator's discretion.
Trial: NCT01856790
Drug: liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide is a long-acting analog of human glucagon like peptide-1 (GLP-1) that works as a GLP-1 receptor agonist
Trial: NCT02584504
Drug: Alirocumab
RxNorm normalized name: Alirocumab
DrugBank: Alirocumab (DB09302)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
Trial: NCT02584504
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 5 mg tablet orally.
Trial: NCT00709371
Drug: Zonisamide SR placebo/ bupropion SR placebo
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 placebo combination tablets twice daily for 16 weeks (maintenance period)
Trial: NCT00709371
Drug: Zonisamide SR placebo/ bupropion SR 360 mg/day
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 placebo and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
Trial: NCT00709371
Drug: Zonisamide SR 120 mg/day/ bupropion SR placebo
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 zonisamide SR 30 mg and placebo combination tablets, twice daily for 16 weeks (maintenance period)
Trial: NCT00709371
Drug: Zonisamide SR 360 mg/day/ bupropion SR placebo
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 zonisamide SR 90 mg and placebo combination tablets, twice daily for 16 weeks (maintenance period)
Trial: NCT00709371
Drug: Zonisamide SR 120 mg/day/ bupropion SR 360 mg/day
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 zonisamide SR 30 mg and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
Trial: NCT00709371
Drug: Zonisamide SR 360 mg/day/ bupropion SR 360 mg/day
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 zonisamide SR 90 mg and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
Trial: NCT03012113
Drug: Mirabegron
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02502266
Drug: Cediranib
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02502266
Drug: Cediranib Maleate
RxNorm normalized name: maleate
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02502266
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT02502266
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT02502266
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02502266
Drug: Topotecan Hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00539838
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral repeating dose
Trial: NCT00539838
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT00539838
Drug: Ocrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT00880529
Drug: IV opioid administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient controlled analgesia with IV narcotics
Trial: NCT00052728
Drug: tamoxifen citrate
RxNorm normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00052728
Drug: tipifarnib
RxNorm normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00724906
Drug: 123 I - ALTROPANE®
DrugBank: Altropane (DB04947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8.0 mCi (±1.0 mCi) will be administered intravenously to each subject.
Trial: NCT03274804
Drug: Maraviroc
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maraviroc will be administered perorally on day 1 to 21 of each cycle (d1-21; qd22)
Trial: NCT01536483
Drug: Butyrate enemas
RxNorm normalized name: butyrate
DrugBank: Butyric Acid (DB03568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seven enemas~* Possibility to delay from 24 to 48 hours the procedure in case of clinical poor tolerance(maximum two enemas postponed and delayed at PND12 and PND13)~* The study remains blinded for the investigation team through the intervention of a clinical research nurse~* According to the procedure previously described by Nakaoka et al. (2009), a lubricated Foley catheter Ch 6 will be introduced into the rectum, the balloon will be inflated with 1 ml water for injections. Butyrate solution will be placed in a bag placed 50 cm above the child. Therefore, treatment administration will be performed at a controlled pressure of 50 cm H2O without any manual intervention~* Installation time and retention is setted at 15 minutes~* Treatment units will be directly placed in the incubator 30 min before the procedure to warm the enema to +36°C~* Per-treatment clinical monitoring of the tolerance will be performed by a neonatologist
Trial: NCT02514668
Drug: Isatuximab
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Trial: NCT04409288
Drug: Apalutamide
RxNorm normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Androgen receptor inhibitor.
Trial: NCT04409288
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Androgern receptor inhibitor
Trial: NCT00079924
Drug: teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00079924
Drug: aldrenodate
DrugBank: Date (DB10632)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00079924
Drug: raloxifene
RxNorm normalized name: Raloxifene
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01660893
Drug: Tetracaine HCl 3% and oxymetazoline HCl 0.05%
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 unilateral intranasal sprays per dose
Trial: NCT01013779
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: During radiotherapy: Carboplatin (AUC2) commences on day 1 of radiation and is repeated at weekly intervals on days 8, 15, 22 and 29 (of radiation).~After radiotherapy: 3 weeks after completing radiotherapy, 3 cycles of 3 weekly carboplatin (AUC4.5) intravenously on day 1.
Trial: NCT01013779
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After Radiotherapy: 3 weeks after completing the radiation therapy, 3 cycles of 3 weekly etoposide (80mg/M2/day) intravenously days 1-3
Trial: NCT00330668
Drug: rh IGF-1 (mecasermin)
RxNorm normalized name: VEXXON-IGF-1
DrugBank: Mecasermin (DB01277)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients from untreated arm for prior study MS301 (NCT00125164) were randomized to a dose of either 80 or 120 mcg/kg twice daily. For patients receiving active treatment in previous study MS 301 (NCT00125164), they started on a dose of 80 or 120 mcg/kg twice daily based on the dose reached at end of the previous study. Following a protocol amendment in May 2009, all patients were switched to once daily doses of 160 µg/kg, escalated to a targeted maximum dose of 240 µg/kg.
Trial: NCT01975610
Drug: CC-292
RxNorm normalized name: BTK inhibitor CC-292
DrugBank: Spebrutinib (DB11764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 mg PO daily (250 mg in the AM and 125 mg in the PM for 28 days)
Trial: NCT01399008
Drug: Arhalofenate
RxNorm normalized name: Arhalofenate
DrugBank: Arhalofenate (DB11811)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arhalofenate 400 and 600 mgs over-encapsulated tablets once daily for 4 weeks or Allopurinol 300 mg once daily for 4 weeks
Trial: NCT01399008
Drug: Allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol 300 mg as active comparator